TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05714293

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT scan with contrast medium
Description: Multi-detector CT scan (if possible with prospective-ECG gated sequential scan) with contrast medium injection of nonionic contrast agent. All CT datasets will be analysed for the qualitative and quantitative assessment of the aortic root. The coronary height will be assessed at baseline in relation to the aortic annulus and in relation to the stent of the bioprostheses after aortic valve replacement.
Study: NCT02544815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: Digoxin 0.25 mg pills

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills
Study: NCT06636487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pulmonary tele-rehabilitation (PTR)
Description: PTR is delivered from promoter hospital to a group of 3 - 5 patients who exercise at home and communicate via tablet-camera. Each session is 60 min; 35 min exercise/ 25 min patient education, two times per week for a duration of 10-weeks.~Specific exercises are evidence-based; been used in several intervention studies on patients with CRD (eg. COPD). Exercises involves larger muscle groups with 50/50 exercises for upper and lower extremities. Volume, intensity and content exercise protocol follow both national and international exercise recommendations. The education sessions consist of dialogue, reflections around empowerment and better living with CRD. Every sixth education session consists of 25 min Mindfulness exercises developed for CRD patients.~After 10-weeks of PTR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation (HPR)
Description: HPR is an individual self-initiated home-based PR aiming to achieve 20 min of self-initiated muscle endurance based exercise; 3-days/weekly for 10-weeks. Exercises are evidence based; used in several intervention studies on patients with CRD (eg. COPD) and involves larger muscle groups with 50/50 exercises for upper/lower extremities.~First session is a home visit by a respiratory physiotherapist. During the visit the physiotherapist and patient establish exercise goals, exercise prescription and provision of access to mindfulness exercises and an educationbook. The home visit is followed by one weekly session for 10-weeks. A menu of topics relevant to CRD and self-management is discussed. A session is delivered from promoter hospital via tablet-camera or telephone call (patients preference).~After 10-weeks of HPR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Receive usual care; medication, scheduled follow up visit and possible phone contact with GP and the outpatient respiratory department. Except for assessment visits 10-, 35-, and 75-weeks from baseline no intervention is offered. If a patient changes their decision and wishes to participate in a conventional hospital- or community-based PR program, it will be granted as this is a highly recommended treatment (e.g. rehabilitation after hospital admitted exacerbation).
Study: NCT06631339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light Intervention
Description: LEDs mimicking the spectrum of sunlight (4000K) administered daily for 1 academic year, every school day, for the entire school day. The light levels generated by these LEDs will fluctuate throughout the day but will remain under 1000 lux.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Intervention
Description: Smart-phone application (LightUP) will be synced daily to a child-worn light and activity sensor and will allow parents to track their children's outdoor time and exposure to brighter light levels across the day. The application will also nudge parents to increase their child's exposure to light (e.g., increase time outdoors, or sitting next to a window indoors) after school hours for better myopia prevention and control. i-LightUP aims to gradually assist parents in helping their children reach the ultimate goal of spending at least 2 hours per day in brighter light conditions (e.g., above 1000 lux).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Standard Classroom Lighting + Sham LightUP phone application
Study: NCT05726630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divozilimab
Description: anti CD20 monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06258304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIGA-564
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIGA-564
Description: Administered by intravenous infusion
Study: NCT05568095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Intravenous (IV) Aqueous Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: IV Aqueous Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Oral Tablets
Study: NCT05251428

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excision of the A1 pulley
Description: Participants will undergo excision of the A1 pulley. Wounds will then be irrigated and closed in the standard fashion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision of the A1 pulley in the standard fashion
Description: Participants will undergo incision of the A1 pulley in the standard fashion. Wounds will then be irrigated and closed in the standard fashion.
Study: NCT05568095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: IV Aqueous Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: IV Aqueous Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: IV Aqueous Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: IV Aqueous Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV Aqueous Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: IV Aqueous Solution
Study: NCT05501704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Taken orally
Study: NCT05568095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: IV Aqueous Solution
Study: NCT04920292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxfendazole
Description: Oxfendazole is a benzimidazole anthelminthic drug.
Study: NCT05920395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Description: Patients lie supine on the treatment bed, and after routine disinfection, a 0.30×60mm or 0.30×40mm disposable sterile acupuncture needle is inserted directly into the acupoint. Once obtaining qi, the needle is manipulated with even reinforcing and reducing techniques to maintain needle sensation. Acupoints selected include Zhongwan, Zusanli, Neiguan, and Tianshu, connected to the 6805-All electro-acupuncture therapy device. Zhongtuo and Tianshu acupoints are connected to a set of electrodes, with the positive pole connected to Zhongtuo and the negative pole connected to one side of Tianshu. The stimulation uses sparse and dense wave pulses with a frequency of 2Hz/100Hz, with the stimulation intensity determined based on individual patient tolerance. Each session lasts for 30 minutes, with a treatment frequency of once every other day, for a total of 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Description: Patients lie supine on the treatment bed, and after routine disinfection, a 0.30×60mm or 0.30×40mm disposable sterile acupuncture needle is inserted directly into the acupoint. Once obtaining qi, the needle is manipulated with even reinforcing and reducing techniques to maintain needle sensation. Acupoints selected include Zhongwan, Zusanli, Neiguan, and Tianshu, connected to the 6805-All electro-acupuncture therapy device. Zhongtuo and Tianshu acupoints are connected to a set of electrodes, with the positive pole connected to Zhongtuo and the negative pole connected to one side of Tianshu. The stimulation uses sparse and dense wave pulses with a frequency of 2Hz/100Hz, with the stimulation intensity determined based on individual patient tolerance. Each session lasts for 30 minutes, with a treatment frequency of once every other day, for a total of 4 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham electro-acupuncture group
Description: Shallow acupuncture needles are used and then disconnected from the electrode. They are tied with black tape and connected to the sham electrode. The device is not powered on, and the rest of the treatment is the same as the electro-acupuncture group.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham electro-acupuncture group
Description: Shallow acupuncture needles are used and then disconnected from the electrode. They are tied with black tape and connected to the sham electrode. The device is not powered on, and the rest of the treatment is the same as the electro-acupuncture group.
Study: NCT04920292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxfendazole
Description: Oxfendazole is a benzimidazole anthelminthic drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxfendazole
Description: Oxfendazole is a benzimidazole anthelminthic drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo tablet is made using the same non-active ingredients and matches the investigational tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo tablet is made using the same non-active ingredients and matches the investigational tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo tablet is made using the same non-active ingredients and matches the investigational tablet.
Study: NCT04869917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid intervention
Description: * Displays information about the benefits and risks of ILI and metformin~* Asks open-ended questions: What am I willing to do to prevent T2D? and What do I need to prevent T2D?~* Prompts patients to commit to immediate next steps~* Health educator schedules interested patients for first ILI session or sends message to provider about patients' interest in starting metformin, if chosen
Study: NCT05501704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Subcutaneous (under the skin) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Subcutaneous (under the skin) injection
Study: NCT04778358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin Delta, Recombinant
Description: 15 µg of follitropin delta will be administered subcutaneously daily
Study: NCT05501704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Subcutaneous (under the skin) injection
Study: NCT05871437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier granule
Description: Huaier Granules: oral administration, 10g once, 3 times a day, used for 1 year, or intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that they no longer benefit. If the patient experiences grade 3-5 (NCI CTC AE V5.0) adverse reactions related to Huai'er granules, and the adverse reactions do not recover after 2 weeks (returning to grade 1 or 2), it can be considered to reduce dosage or stop Huai'er granules treatment. If the medication is suspended for more than 2 weeks, the medication can be interrupted according to the judgment of the researcher. If the same adverse reaction occurs again, the Huaier granules will be permanently discontinued.
Study: NCT05501704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Taken orally
Study: NCT05038332

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultra-hypofractionated radiation therapy
Description: 34 Gy in 5 fractions to prostate bed, every other day, M-F, \~2 weeks (25 Gy in 5 fractions to pelvic lymph nodes if included)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Moderately Hypo-fractionated Radiation Therapy
Description: 55 Gy in 20 fractions to prostate bed, daily, M-F, 4 weeks (42 Gy in 20 fractions to pelvic lymph nodes if included)
Study: NCT05299606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transbronchial Microwave Ablation
Description: Transbronchial microwave ablation will be performed using the NEUWAVE FLEX Microwave Ablation System and Accessories on oligometastatic tumors in the peripheral lung, guided by the Auris MONARCH Platform for visualization and access while using cone beam CT (computed tomography) to confirm probe tip placement and final ablation zone.
Study: NCT05615558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Controlled dietary intervention; all food is provided to participants after being allocated to animal or non-animal dietary protein, for a duration of 5 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Controlled dietary intervention; all food is provided to participants after being allocated to animal or non-animal dietary protein, for a duration of 5 weeks.
Study: NCT05590312

Intervention type: OTHER
Intervention: general anesthesia
Description: All patients will undergo general anesthesia. Group D will receive fresh gas flow of 1 l/min and Group Y will receive fresh gas flow of 4 l/min.

Intervention type: OTHER
Intervention: general anesthesia
Description: All patients will undergo general anesthesia. Group D will receive fresh gas flow of 1 l/min and Group Y will receive fresh gas flow of 4 l/min.
Study: NCT06494488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPA
Description: Fish oil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA
Description: Fish oil
Study: NCT06360536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: A home-based resistance training condition that is delivered through a web-based platform.
Study: NCT06642428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy + vitamin D2
Description: Before the start of treatment and every 3 weeks thereafter, participants will receive injections of vitamin D2 at a dosage of 10 mg until the completion of neoadjuvant therapy. They will undergo the standard neoadjuvant regimen, which includes the 10 mg injection of vitamin D2 per cycle during the therapy. The dosage of neoadjuvant drugs may be tailored based on the physician's clinical judgment.

Intervention type: DRUG
Group type: OTHER
Intervention: Neoadjuvant therapy
Description: Participants will receive the standard neoadjuvant regimen during each cycle of neoadjuvant therapy. The dosage of the neoadjuvant drugs may be tailored based on the physician's clinical judgment.
Study: NCT06082739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Stretching exercises with and without a bolster, ball, or foam roller.
Study: NCT06577675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group programme for DBT training
Description: This programme comprises 16 sessions over approximately 5 to 6 months, with one 2.5-hour session every week in a closed group of 8 patients. These sessions will be supervised by two or four carers trained in DBT.
Study: NCT06249984

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT05174806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Pravibismane
Description: Topical Pravibismane

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of care treatment without investigational topical pravibismane (MBN-101) or other topical antibiotics.
Study: NCT06095284

Intervention type: OTHER
Intervention: Pre-Extraction Phase
Description: This intervention requires the following procedures: Submitting data use agreement, MDS request defined and developed, Part D request, CMS public use file request defines and develop questionnaire
Study: NCT04869917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid intervention
Description: * Displays information about the benefits and risks of ILI and metformin~* Asks open-ended questions: What am I willing to do to prevent T2D? and What do I need to prevent T2D?~* Prompts patients to commit to immediate next steps~* Health educator schedules interested patients for first ILI session or sends message to provider about patients' interest in starting metformin, if chosen

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging intervention
Description: * Defines prediabetes and includes individualized A1c values~* Present benefits and risks of intensive lifestyle intervention and metformin~* States that other prediabetic Erie patients are adopting intensive lifestyle intervention and metformin~* Encourages initiating intensive lifestyle intervention or discussing metformin with provider~* Include selected behavioral content from diabetes prevention program~* Initial message with automatic opt-in, allows opt-out for messages~* Subsequent messages include: information about T2D risk and treatments; prompts to directly schedule intensive lifestyle intervention or office visit to discuss metformin; selected behavioral content from diabetes prevention programming

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging intervention
Description: * Defines prediabetes and includes individualized A1c values~* Present benefits and risks of intensive lifestyle intervention and metformin~* States that other prediabetic Erie patients are adopting intensive lifestyle intervention and metformin~* Encourages initiating intensive lifestyle intervention or discussing metformin with provider~* Include selected behavioral content from diabetes prevention program~* Initial message with automatic opt-in, allows opt-out for messages~* Subsequent messages include: information about T2D risk and treatments; prompts to directly schedule intensive lifestyle intervention or office visit to discuss metformin; selected behavioral content from diabetes prevention programming

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Patients receiving care at non-intervention clinic sites will not be exposed to treatment intervention.
Study: NCT05964868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: Patients will receive post-operative liposomal bupivacaine (EXPAREL®) at the surgical site at the completion of their septorhinoplasty.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% bupivacaine with 1:200,000 epinephrine
Description: Non-liposomal encapsulated bupivacaine at the surgical site at the completion of septorhinoplasty.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Saline solution
Description: This group will receive a one-time 5 mL injection of saline post-operatively at the surgical site.
Study: NCT04122690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PDAE
Description: Participants with PD will dance the follower role only and will dance with new partners (individuals without PD) every 15-20 minutes, a widely practiced method considered by the dance teaching community to enhance learning. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Frequent repetition and musical stereotypes may foster implicit learning or muscle memory (i.e., motor learning, or procedural memory that involves consolidating a specific motor task into memory through repetition). Participants will not be required to memorize specific step patterns but will learn new steps in each class
Study: NCT04122690

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WAE
Description: The participants will receive equal contact and monitoring from study staff. WAE participants will report to the same facility and interact with the same interventionist and assistants. The participants will participate in sessions focused on at least 60 minutes of walking with breaks ad libitum, and 1/2 hour balance and stretching. The investigators have a designated, safe and non-cluttered area for walking. WAE will also take place in groups, with research volunteers and assistants to ensure that PDAE and WAE participants both receive a socially engaging intervention
Study: NCT06018116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg
Description: nonsteroidal antiandrogen
Study: NCT06095284

Intervention type: OTHER
Intervention: Extraction Phase
Description: Procedures include: Access VRDC for 2 years, Crosswalk CMS files and MDS using ID's, Preliminary analysis for validity/accuracy, Request revision/resubmission, Linked dataset created in VRDC and Distribute Questionnaire

Intervention type: OTHER
Intervention: Extraction Phase
Description: Procedures include: Access VRDC for 2 years, Crosswalk CMS files and MDS using ID's, Preliminary analysis for validity/accuracy, Request revision/resubmission, Linked dataset created in VRDC and Distribute Questionnaire

Intervention type: OTHER
Intervention: Post-Extraction Phase
Description: Procedures include: De-identified data securely stored, analysis, dissemination and knowledge translation